EGFR and non-small cell lung carcinoma: The IIIb/IV safety trial CheckMate 153 of nivolumab in patients with advanced or metastatic squamous or non-squamous NSCLC who received at least one prior line found that partial response rate was only 11% (n = 55) in the EGFR-mutated subgroup compared with 16% (n = 300) in the EGFR wild-type subgroup (108).